Journal: Neoplasia (New York, N.Y.)
Article Title: PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy
doi: 10.1016/j.neo.2026.101305
Figure Lengend Snippet: Inhibition of cervical cancer cell lines by PI3K α inhibitors. The maximum dose for each cell line was selected, and the percentage inhibition was compared with the corresponding control. (A) Alpelisib (BYL-719). (B) Inavolisib (GDC-0077). All cell lines have PIK3CA mutations except SiHa. **** = p < 0.0001 by one-way ANOVA and Dunnett’s multiple comparison test. <20% inhibition interpreted as no or negative response.
Article Snippet: GDC-0077 was also purchased from MedChem Express (Cat# HY-101562.
Techniques: Inhibition, Control, Comparison